PMID- 37520615
OWN - NLM
STAT- Publisher
LR  - 20230801
IS  - 1939-4551 (Print)
IS  - 1939-4551 (Electronic)
IS  - 1939-4551 (Linking)
VI  - 16
IP  - 7
DP  - 2023 Jul
TI  - Birch-induced allergic rhinitis: Results of exposure during nasal allergen 
      challenge, environmental chamber, and pollen season.
PG  - 100801
LID - 10.1016/j.waojou.2023.100801 [doi]
LID - 100801
AB  - BACKGROUND: Pollen variation can affect field study data quality. Nasal allergen 
      challenge (NAC) is considered the gold standard for evaluating allergic rhinitis, 
      while environmental exposure chambers (EECs) are mainly used in phase 2 drug 
      development studies. We aimed to study birch-induced allergic rhinitis under 3 
      different conditions. METHODS: This study included 30 participants allergic to 
      birch pollen, based on birch skin prick test, specific immunoglobulin E (IgE), 
      and positive NAC. Participants were exposed to placebo twice, followed by 2 
      consecutive 4-h birch airborne exposures, repeated on 2 occasions to evaluate 
      reproducibility and priming effect. Nasal response was defined as total corrected 
      nasal symptom score (DeltaTNSS) >/= 5 during NAC and EEC. The primary end-point was to 
      measure TNSS during the last 2 h of first allergen exposure. TNSS was also 
      analyzed during natural exposure. RESULTS: The dose most commonly yielding 
      positive TNSS during NAC was 175.2 ng/200 muL. Eighteen participants experienced 
      DeltaTNSS >/=5 during the last 2 h of the first exposure, whereas 21 had positive 
      responses at all 4 exposures. Mean DeltaTNSS was 1 with placebo versus 6 with birch. 
      Exposures were reproducible, with no observed priming effect. Airborne Bet v 1 
      was 25 ng/m(3), while the pollen measurement was 279/m(3) during pollen season. 
      TNSS reached 5 in 67.9% of participants during peak pollen season. CONCLUSION: 
      EEC outcomes were similar to those obtained with NAC and natural exposure, 
      suggesting the usefulness of EEC in allergic rhinitis studies. The primary 
      end-point was reached, as 60% of participants experienced nasal responses.
CI  - (c) 2023 The Authors.
FAU - Gherasim, Alina
AU  - Gherasim A
AD  - ALYATEC Environmental Exposure Chamber, 1 place de l'Hopital, Strasbourg, France.
FAU - Dietsch, Frank
AU  - Dietsch F
AD  - ALYATEC Environmental Exposure Chamber, 1 place de l'Hopital, Strasbourg, France.
FAU - Beck, Marine
AU  - Beck M
AD  - ALYATEC Environmental Exposure Chamber, 1 place de l'Hopital, Strasbourg, France.
FAU - Domis, Nathalie
AU  - Domis N
AD  - ALYATEC Environmental Exposure Chamber, 1 place de l'Hopital, Strasbourg, France.
FAU - de Blay, Frederic
AU  - de Blay F
AD  - ALYATEC Environmental Exposure Chamber, 1 place de l'Hopital, Strasbourg, France.
AD  - Chest Diseases Department, Strasbourg University Hospital, Strasbourg, France.
AD  - Federation of Translational Medicine EA 3070, University of Strasbourg, 
      Strasbourg, France.
LA  - eng
PT  - Journal Article
DEP - 20230715
PL  - United States
TA  - World Allergy Organ J
JT  - The World Allergy Organization journal
JID - 101481283
PMC - PMC10384658
OTO - NOTNLM
OT  - Allergic rhinitis
OT  - Birch allergy
OT  - Birch pollen
OT  - Environmental exposure chamber
OT  - Nasal allergen challenge
COIS- Alina Gherasim, Frank Dietsch, and Marine Beck are ALYATEC employees. Nathalie 
      Domis is an ALYATEC co-founder and employee. FdB is the medical expert, 
      co-founder, and shareholder of ALYATEC. Frederic de Blay reports grants from 
      ASTRAZENECA, CHIESI, GSK, REGENERON, NOVARTIS, and STALLERGENES GREER, and 
      personal fees from ALK ABELLO, ASTRAZENECA, CHIESI, MENARINI, NOVARTIS, and 
      STALLERGENES GREER.
EDAT- 2023/07/31 06:43
MHDA- 2023/07/31 06:43
PMCR- 2023/07/15
CRDT- 2023/07/31 04:54
PHST- 2023/03/01 00:00 [received]
PHST- 2023/06/22 00:00 [revised]
PHST- 2023/06/28 00:00 [accepted]
PHST- 2023/07/31 06:43 [medline]
PHST- 2023/07/31 06:43 [pubmed]
PHST- 2023/07/31 04:54 [entrez]
PHST- 2023/07/15 00:00 [pmc-release]
AID - S1939-4551(23)00061-3 [pii]
AID - 100801 [pii]
AID - 10.1016/j.waojou.2023.100801 [doi]
PST - epublish
SO  - World Allergy Organ J. 2023 Jul 15;16(7):100801. doi: 
      10.1016/j.waojou.2023.100801. eCollection 2023 Jul.